Abstract
Purpose :
To identify risk factors of recurrence of macular edema in branch retinal vein occlusion (BRVO) after intravitreal bevacizumab (IVB) injection.
Methods :
The records of 63 patients who underwent IVB injection for macular edema secondary to BRVO with at least 6 months of follow-up were reviewed. Patients were evaluated at baseline with fluorescein angiography (FA), optical coherence tomography (OCT), and ultra-wide-field fundus photography (WFP). During follow-up, OCT and WFP were repeated. The area of retinal hemorrhage, central retinal thickness (CRT), area (mm2) of abnormal capillary non-perfusion within the 1-mm (NPA1) and 3-mm (NPA3) zones of the ETDRS circle, foveal capillary filling time, degree (°) of foveal capillary network destruction, and FA pattern were analyzed.
Results :
The records of 63 patients who underwent IVB injection for macular edema secondary to BRVO with at least 6 months of follow-up were reviewed. Patients were evaluated at baseline with fluorescein angiography (FA), optical coherence tomography (OCT), and ultra-wide-field fundus photography (WFP). During follow-up, OCT and WFP were repeated. The area of retinal hemorrhage, central retinal thickness (CRT), area (mm2) of abnormal capillary non-perfusion within the 1-mm (NPA1) and 3-mm (NPA3) zones of the ETDRS circle, foveal capillary filling time, degree (°) of foveal capillary network destruction, and FA pattern were analyzed.
Conclusions :
In BRVO patients with non-perfusion of more than half of the 1-mm zone of the ETDRS circle or whose initial CRT is more than 570 µm, a high degree of suspicion of macular edema recurrence within 6 months of IVB injection is warranted.
This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.